0000000000105175

AUTHOR

A Carbone

SYNTHESIS OF 2-TRIAZENO-PYRROLO-PYRIDINES A NEW CLASS OF TRIAZENES WITH ANTITUMOR ACTIVITY

research product

Novel conception materials based on polymeric Matrix for H2 storage

research product

Progettazione e sintesi di 2,3-diaril-1,3-tiazolidin-4-oni nuovi HIV-1 NNRTIs.

research product

SYNTHESIS OF 3-(2-PHENYL-1,3-THIAZOL-4-YL)-1H-INDOLES, NEW DERIVATIVES WITH POTENTIAL ANTINEOPLASTIC ACTIVITY

research product

Limits on neutral Higgs boson production in the forward region in $pp$ collisions at $\sqrt{s} = 7$ TeV

Limits on the cross-section times branching fraction for neutral Higgs bosons, produced in p p collisions at root s = 7 TeV, and decaying to two tau leptons with pseudorapidities between 2.0 and 4.5, are presented. The result is based on a dataset, corresponding to an integrated luminosity of 1.0 fb(-1), collected with the LHCb detector. Candidates are identified by reconstructing final states with two muons, a muon and an electron, a muon and a hadron, or an electron and a hadron. A model independent upper limit at the 95% confidence level is set on a neutral Higgs boson cross-section times branching fraction. It varies from 8.6 pb for a Higgs boson mass of 90 GeV to 0.7 pb for a Higgs bos…

research product

SYNTHESIS OF PYRROLO[3,4-H]QUINAZOLIN-2-ONE A NEW RING SYSTEM WITH POTENTIAL PHOTOTHERAPEUTIC ACTIVITY

research product

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

research product

SINTESI DI 2,5-BIS[3-(7-AZAINDOLIL)]TIOFENI ANALOGHI DELLA NORTOPSENTINA

research product

De novo drug design and synthesis of new HIV-1 NNRTIs

research product

4-AZA E 7-AZA-ISOINDOLO[1,2-a]CHINOSSALINE: DUE NUOVI SISTEMI ETEROCICLICI A POTENZIALE ATTIVITÀ ANTITUMORALE

research product

PIRROLO[3,2-H]CHINOLINONI A POTENZIALE ATTIVITA' FOTOCHEMIOTERAPICA

research product

PYRROLO[3,2-H]QUINOLINONES AS POTENTIAL PHOTOREAGENTS TOWARDS DNA

research product

Design and synthesis of new 2,3-diaryl-1,3-thiazolidin-4-one HIV-1 RT-inhibitors.

research product

Sintesi ed Attività Antitumorale di Bis(indolil)eterocicli: Analoghi dell’Alcaloide Marino Nortopsentina

research product

Progettazione di nuovi agenti anti-HIV e individuazione di nuovi lead compound

research product

SINTESI DELL'ISONETROPSINA E DELL'ISOMERO DIMERICO DELLA DISTAMICIA A

research product

Search for CP violation in D (+/-) -> (KSK +/-)-K-0 and D-s(+/-) -> K-S(0)pi(+/-) decays

A search for \CP violation in Cabibbo-suppressed $D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}$ and $D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}$ decays is performed using $pp$ collision data, corresponding to an integrated luminosity of 3~fb$^{-1}$, recorded by the LHCb experiment. The individual $CP$-violating asymmetries are measured to be \begin{eqnarray*} \mathcal{A}_{CP}^{D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}} & = & (+0.03 \pm 0.17 \pm 0.14) \% \mathcal{A}_{CP}^{D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}} & = & (+0.38 \pm 0.46 \pm 0.17) \%, \end{eqnarray*} assuming that $CP$ violation in the Cabibbo-favoured decays is negligible. A combination of the measured asymmet…

research product

Measurement of polarization amplitudes and CP asymmetries in B 0 → Φk *(892)0

An angular analysis of the decay $B^0 \to \phi K^*(892)^0$ is reported based on a $pp$ collision data sample, corresponding to an integrated luminosity of 1.0 fb$^{-1}$, collected at a centre-of-mass energy of $\sqrt{s} = 7$ TeV with the LHCb detector. The P-wave amplitudes and phases are measured with a greater precision than by previous experiments, and confirm about equal amounts of longitudinal and transverse polarization. The S-wave $K^+ \pi^-$ and $K^+K^-$ contributions are taken into account and found to be significant. A comparison of the $B^0 \to \phi K^*(892)^0$ and $\bar{B}^0 \to \phi \bar{K}^*(892)^0$ results shows no evidence for direct CP violation in the rate asymmetry, in th…

research product

2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Several 1,3-thiazolidin-4-ones bearing a 2,6-dihalophenyl group at C-2 and a substituted pyrimidin-2-yl ring at the N-3 were synthesised and evaluated as anti-HIV agents. The results of the in vitro tests showed that some of them were highly effective inhibitors of human immunodeficiency virus type-1 (HIV-1) replication at 10–40 nM concentrations with minimal cytotoxicity. Structure–activity relationship studies revealed that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus had a significant impact on the in vitro anti-HIV activity of this class of potent antiretroviral agents. The compounds had significantly reduced activity against the characteristic N…

research product

Synthesis and biological evaluation of pyrrolo[3’,2’:6,7]cyclohepta[1,2-d]pyrimidin-2-amines

research product

Angular analysis of charged and neutral B → Kμ + μ − decays

The angular distributions of the rare decays B → K+µ+µ- and B0 → K0 <inf>a</inf>Sμ+μ- are studied with data corresponding to 3 fb-1 of integrated luminosity, collected in proton-proton collisions at 7 and 8TeV centre-of-mass energies with the LHCb detector. The angular distribution is described by two parameters, FH and the forward-backward asymmetry of the dimuon system AFB, which are determined in bins of the dimuon mass squared. The parameter F<inf>H</inf> is a measure of the contribution from (pseudo)scalar and tensor amplitudes to the decay width. The measurements of A<inf>FB</inf> and F<inf>H</inf> reported here are the most precise to d…

research product

3-[2-(1H-INDOL-3-YL)-1,3-THIAZOL-4-YL)-1H-4-AZAINDOLE: A NEW SERIES OF NORTOPSENTIN HETEROANALOGUES WITH ANTIPROLIFERATIVE ACTIVITY

research product

Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents

Several 2,3-diaryl-1,3-thiazolidin-4-ones were synthesized and evaluated as anti-HIV agents. The results of the in vitro tests showed that some of them were highly effective inhibitors of HIV-1 replication at 30-50 nM concentrations with minimal cytotoxicity, thereby acting as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs).

research product

Measurement of the B-0 -> K*(0) e(+) e(-) branching fraction at low dilepton mass

The branching fraction of the rare decay B-0 -> K*(0) e(+) e(-) in the dilepton mass region from 30 to 1000 MeV/c(2) has been measured by the LHCb experiment, using pp collision data, corresponding to an integrated luminosity of 1.0 fb(-1), at a centre-of-mass energy of 7 TeV. The decay mode B-0 -> J/psi (e(+) e(-)) K*(0) is utilized as a normalization channel. The branching fraction B(B-0 -> K*(0) e(+) e(-)) is measured to be B(B-0 -> K*(0) e(+) e(-))(30-1000 MeV/c2) = (3.1(-0.8)(-0.3)(+0.9)(+0.2) +/- 0.2) x 10(-7) where the fi rst error is statistical, the second is systematic, and the third comes from the uncertainties on the B-0 -> J/K*(0) and J/psi -> e(+) e(-) branching fractions.

research product